Recent Analysts’ Ratings Changes for Medpace (MEDP)

Several brokerages have updated their recommendations and price targets on shares of Medpace (NASDAQ: MEDP) in the last few weeks:

• 10/26/2026 – Medpace had its price target raised by BMO Capital Markets from $600.00 to $670.00. They now have a “market perform” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by Truist Financial from $609.00 to $633.00. They now have a “hold” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by UBS Group from $673.00 to $700.00. They now have a “neutral” rating on the stock.
• 10/23/2026 – Medpace was given a new $730.00 price target by Mizuho.
• 10/23/2026 – Medpace was given a new $699.00 price target by Robert W. Baird.
• 10/23/2026 – Medpace had its price target raised by Barclays from $625.00 to $675.00. They now have an “equal weight” rating on the stock.
• 10/23/2026 – Medpace had its price target raised by TD Cowen from $492.00 to $673.00. They now have a “hold” rating on the stock.
• 10/8/2026 – Medpace was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/7/2026 – Medpace had its price target raised by Mizuho from $665.00 to $700.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Medpace had its price target raised by Barclays from $600.00 to $625.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Medpace is now covered by UBS Group. They set a “neutral” rating and a $673.00 price target on the stock.
• 9/30/2026 – Medpace was upgraded by UBS Group from “sell” to “hold”. They now have a $673.00 price target on the stock, up from $405.00.
• 9/14/2026 – Medpace had its “hold” rating reaffirmed by Jefferies Financial Group.

Insider Activity

In other news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 321,402 shares of company stock worth $199,162,324 in the last quarter. 20.50% of the stock is currently owned by corporate insiders.

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.